Erythropoietin for the treatment of anemia in patients with hematologic disorders

This article introduces common data and our experience concerning the treatment with recombinant human erythropoietin anemia (r-HuEPO) in anemic patients with different disorders. We cited as an example some results of Eprex (Janssen-Cilag) therapy for patients with hematologic disorders in Russia....

Full description

Bibliographic Details
Main Authors: R. A. Podgurskaya, V. V. Pshibieva
Format: Article
Language:Russian
Published: ABV-press 2022-11-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/642
_version_ 1826557101062750208
author R. A. Podgurskaya
V. V. Pshibieva
author_facet R. A. Podgurskaya
V. V. Pshibieva
author_sort R. A. Podgurskaya
collection DOAJ
description This article introduces common data and our experience concerning the treatment with recombinant human erythropoietin anemia (r-HuEPO) in anemic patients with different disorders. We cited as an example some results of Eprex (Janssen-Cilag) therapy for patients with hematologic disorders in Russia. 28 anemic patients treated with Eprex were included in a single center study (CLL 8, lymphomas 2, CIMF 11, MDS 5, AA 2). The majority of patient demonstrated stable increase in hemoglobin levels and erythrocyte counts, improvement of performance status and decrease in transfusion requirements. Erythropoietin was well tolerated. Further studies in order to value long-term effect of Eprex are in progress.
first_indexed 2024-04-09T20:24:29Z
format Article
id doaj.art-928d5e3feb5c4a0eaf3c75cf6136b8ab
institution Directory Open Access Journal
issn 1818-8346
2413-4023
language Russian
last_indexed 2025-03-14T08:23:14Z
publishDate 2022-11-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj.art-928d5e3feb5c4a0eaf3c75cf6136b8ab2025-03-02T13:07:14ZrusABV-pressОнкогематология1818-83462413-40232022-11-0102373810.17650/1818-8346-2007-0-2-37-38520Erythropoietin for the treatment of anemia in patients with hematologic disordersR. A. Podgurskaya0V. V. Pshibieva1St. Petersburg Medical Academy for Postgraduate Medical Education, City Hospital №15St. Petersburg Medical Academy for Postgraduate Medical Education, City Hospital №15This article introduces common data and our experience concerning the treatment with recombinant human erythropoietin anemia (r-HuEPO) in anemic patients with different disorders. We cited as an example some results of Eprex (Janssen-Cilag) therapy for patients with hematologic disorders in Russia. 28 anemic patients treated with Eprex were included in a single center study (CLL 8, lymphomas 2, CIMF 11, MDS 5, AA 2). The majority of patient demonstrated stable increase in hemoglobin levels and erythrocyte counts, improvement of performance status and decrease in transfusion requirements. Erythropoietin was well tolerated. Further studies in order to value long-term effect of Eprex are in progress.https://oncohematology.abvpress.ru/ongm/article/view/642anemiahematologic malignancieserythropoietinepoeprex
spellingShingle R. A. Podgurskaya
V. V. Pshibieva
Erythropoietin for the treatment of anemia in patients with hematologic disorders
Онкогематология
anemia
hematologic malignancies
erythropoietin
epo
eprex
title Erythropoietin for the treatment of anemia in patients with hematologic disorders
title_full Erythropoietin for the treatment of anemia in patients with hematologic disorders
title_fullStr Erythropoietin for the treatment of anemia in patients with hematologic disorders
title_full_unstemmed Erythropoietin for the treatment of anemia in patients with hematologic disorders
title_short Erythropoietin for the treatment of anemia in patients with hematologic disorders
title_sort erythropoietin for the treatment of anemia in patients with hematologic disorders
topic anemia
hematologic malignancies
erythropoietin
epo
eprex
url https://oncohematology.abvpress.ru/ongm/article/view/642
work_keys_str_mv AT rapodgurskaya erythropoietinforthetreatmentofanemiainpatientswithhematologicdisorders
AT vvpshibieva erythropoietinforthetreatmentofanemiainpatientswithhematologicdisorders